News Column

Studies from University of Lyon in the Area of Gene Therapy Reported (Hepatitis B Virus Infection Enhances Susceptibility Toward Adeno-Associated...

July 24, 2014



Studies from University of Lyon in the Area of Gene Therapy Reported (Hepatitis B Virus Infection Enhances Susceptibility Toward Adeno-Associated Viral Vector Transduction In Vitro and In Vivo)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Biotechnology. According to news reporting out of Lyon, France, by NewsRx editors, research stated, "Gene therapy has become an accepted concept for the treatment of a variety of different diseases. In contrast to preclinical models, subjects enrolled in clinical trials, including gene therapy, possess a history of infection with microbes that may influence its safety and efficacy."

Our news journalists obtained a quote from the research from the University of Lyon, "Especially, viruses that establish chronic infections in the liver, one of the main targets for in vivo gene therapy, raise important concerns. Among them is the hepatitis B virus (HBV), which has chronically infected more than 350 million people worldwide. Here, we investigated the effect of HBV on adeno-associated viral (AAV) vectors, the most frequently applied gene transfer vehicles for in vivo gene therapy. Unexpectedly, we found that HBV greatly improved AAV transduction in cells replicating HBV and identified HBV protein x (HBx) as a key factor. Whereas HBV-positive and -negative cells were indistinguishable with respect to cell-entry efficiency, significantly higher numbers of AAV vector genomes were successfully delivered to the nucleus in the presence of HBV. The HBV-promoting effect was abolished by inhibitors of phosphatidylinositol 3-kinase (PI3K). PI3K was required for efficient trafficking of AAV to the nucleus and was enhanced in HBV-replicating cells and upon HBx expression. Enhancement of AAV transduction was confirmed in vivo using HBV transgenic mice and could successfully be applied to inhibit HBV progeny release."

According to the news editors, the research concluded: "Our results demonstrate that acute, as well as chronic, infections with unrelated viruses change the intracellular milieu, thereby likely influencing gene therapy outcomes. In the case of HBV, HBx-mediated enhancement of AAV transduction is an advantage that could be exploited for development of novel treatments of HBV infection."

For more information on this research see: Hepatitis B Virus Infection Enhances Susceptibility Toward Adeno-Associated Viral Vector Transduction In Vitro and In Vivo. Hepatology, 2014;59(6):2110-2120. Hepatology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Hepatology - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1527-3350)

Our news journalists report that additional information may be obtained by contacting M. Hosel, University of Lyon, LabEx Ecofect, Lyon, France. Additional authors for this research include J. Lucifora, T. Michler, G. Holz, M. Gruffaz, S. Stahnke, F. Zoulim, D. Durantel, M. Heikenwalder, D. Nierhoff, R. Millet, A. Salvetti, U. Protzer and H. Buning (see also Biotechnology).

Keywords for this news article include: HBV, Lyon, Biotechnology, Viral, France, Europe, Genetics, Virology, Hepatology, DNA Viruses, Gene Therapy, Bioengineering, Liver Diseases, Gastroenterology, Hepatitis B Virus, Orthohepadnavirus, Infectious Disease, Digestive System Diseases, Hepadnaviridae Infections

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters